Home/Pipeline/Sonalleve® MR-HIFU

Sonalleve® MR-HIFU

Uterine Fibroids

CommercialLicensed/Distributed

Key Facts

Indication
Uterine Fibroids
Phase
Commercial
Status
Licensed/Distributed
Company

About Profound Medical

Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.

View full company profile

About Profound Medical

Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.

View full company profile

Therapeutic Areas

Other Uterine Fibroids Drugs

DrugCompanyPhase
Esmya® (ulipristal acetate)OrganonApproved